Great to see Lycia Therapeutics up on the Nasdaq tower in Times Square marking our $75M Series D! Thanks to our supportive syndicate of investors and to the team behind the science. We are looking forward to advancing our #LYTAC degraders as potential treatments for patients needing better options for food allergies, Graves' disease and other conditions.
Lycia Therapeutics
Biotechnology Research
South San Francisco, California 6,887 followers
Building the leading extracellular protein degradation company
About us
At Lycia, we aim to eliminate the source of disease using the power of extracellular protein degradation. Our novel LYTAC therapeutics are designed to bind and remove disease-causing extracellular proteins by directing them into the cell for degradation via the lysosome. Focused initially on autoimmune and inflammatory diseases, our platform addresses gaps in targeting proteins outside the cell, offering new hope to patients who urgently need better options.
- Website
-
https://lyciatx.com/
External link for Lycia Therapeutics
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2020
Locations
-
Primary
Get directions
E Jamie Ct
South San Francisco, California 94080, US
Employees at Lycia Therapeutics
Updates
-
We are thrilled to have Amy Bachrodt join Lycia as Chief Financial Officer! Amy brings more than 15 years of finance leadership across private and public biotechnology companies, with deep expertise in capital markets, investor relations, and strategic finance. Her appointment and the promotion of Karen Flick to General Counsel come at an important stage in Lycia’s growth as we advance our two lead assets to early clinical proof-of-concept following promising preclinical data. Read more: https://lnkd.in/g2SugGwa #Autoimmune #Inflammatory #ProteinDegradation #TargetedProteinDegradation
-
-
Today, we announced the completion of an oversubscribed $75 million Series D financing. The news accompanies the appointment of Amy Bachrodt as Lycia’s new Chief Financial Officer and the promotion of Karen Flick to General Counsel. With this financing and strengthened leadership team now in place, Lycia is well-positioned to execute on our clinical programs while advancing the next generation of cataLYTAC degraders, with the near-term goal of demonstrating Phase 1 clinical proof-of-concept in patients. Read more: https://lnkd.in/g2SugGwa #Autoimmune #Inflammatory #ProteinDegradation #TargetedProteinDegradation
-